TENAYA and LUCERNE Two-Year Results from the Phase 3 Neovascular Age-Related Macular Degeneration Trials of Faricimab with Treat-and-Extend Dosing in Year 2

32 biomedical and clinical sciences (for-2020), 3212 ophthalmology and optometry (for-2020), eye disease and disorders of vision (rcdc), clinical trials and supportive activities (rcdc), clinical research (rcdc), neurosciences (rcdc), macular degeneration (rcdc), neurodegenerative (rcdc)